Posts tagged clinical program
Ladenburg starts Bellerophon at buy

Ladenburg Thalmann initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.18 on April 13.

Read More
Wainwright starts Summit Therapeutics at buy

H.C. Wainwright initiated coverage of Summit Therapeutics (NASDAQ:SMMT) with a “buy” rating and $26 price target. The stock closed at $5.50 on Thursday.

Summit has two de-risked assets, with billion-dollar potential, and is conducting clinical programs focused on two genetic diseases: Duchenne muscular dystrophy (DMD) and Clostridium difficile infections (CDI).

Read More
Stifel starts Selecta Biosciences at buy

Stifel launched coverage of Selecta Biosciences (NASDAQ:SELB) with a “buy” rating and $23 price target. The stock closed at $14 on Friday.

“Selecta’s SVP-Rapamycin technology has the potential to open the doors of immunological tolerance and allow patients to be treated with recombinant protein ‘creations’ designed to combat disease,” writes analyst Thomas Shrader.

Read More